X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs CIPLA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES CIPLA PIRAMAL ENTERPRISES/
CIPLA
 
P/E (TTM) x 38.1 45.0 84.8% View Chart
P/BV x 3.8 3.7 102.5% View Chart
Dividend Yield % 0.6 0.3 184.8%  

Financials

 PIRAMAL ENTERPRISES   CIPLA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
CIPLA
Mar-17
PIRAMAL ENTERPRISES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,065622 171.2%   
Low Rs805458 175.6%   
Sales per share (Unadj.) Rs383.0181.9 210.6%  
Earnings per share (Unadj.) Rs55.112.9 428.0%  
Cash flow per share (Unadj.) Rs74.129.3 252.7%  
Dividends per share (Unadj.) Rs17.502.00 875.0%  
Dividend yield (eoy) %1.90.4 505.4%  
Book value per share (Unadj.) Rs719.9155.7 462.4%  
Shares outstanding (eoy) m172.56804.51 21.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.43.0 82.2%   
Avg P/E ratio x17.042.0 40.4%  
P/CF ratio (eoy) x12.618.4 68.5%  
Price / Book Value ratio x1.33.5 37.4%  
Dividend payout %31.815.5 204.4%   
Avg Mkt Cap Rs m161,344434,516 37.1%   
No. of employees `0003.823.0 16.4%   
Total wages/salary Rs m16,89826,338 64.2%   
Avg. sales/employee Rs Th17,472.66,349.1 275.2%   
Avg. wages/employee Rs Th4,466.91,143.0 390.8%   
Avg. net profit/employee Rs Th2,512.8449.3 559.2%   
INCOME DATA
Net Sales Rs m66,099146,302 45.2%  
Other income Rs m2,4252,287 106.0%   
Total revenues Rs m68,524148,589 46.1%   
Gross profit Rs m18,72324,758 75.6%  
Depreciation Rs m3,27413,229 24.8%   
Interest Rs m9,3881,594 589.0%   
Profit before tax Rs m8,48512,222 69.4%   
Minority Interest Rs m30-   
Prior Period Items Rs m1,593-70 -2,278.7%   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,0321,798 57.4%   
Profit after tax Rs m9,50610,354 91.8%  
Gross profit margin %28.316.9 167.4%  
Effective tax rate %12.214.7 82.7%   
Net profit margin %14.47.1 203.2%  
BALANCE SHEET DATA
Current assets Rs m47,48887,370 54.4%   
Current liabilities Rs m104,36233,081 315.5%   
Net working cap to sales %-86.037.1 -231.9%  
Current ratio x0.52.6 17.2%  
Inventory Days Days4187 46.7%  
Debtors Days Days5162 82.1%  
Net fixed assets Rs m26,532111,567 23.8%   
Share capital Rs m3451,609 21.4%   
"Free" reserves Rs m114,024123,645 92.2%   
Net worth Rs m124,221125,254 99.2%   
Long term debt Rs m75,81236,454 208.0%   
Total assets Rs m308,356209,532 147.2%  
Interest coverage x1.98.7 22.0%   
Debt to equity ratio x0.60.3 209.7%  
Sales to assets ratio x0.20.7 30.7%   
Return on assets %6.15.7 107.5%  
Return on equity %7.78.3 92.6%  
Return on capital %10.08.5 117.2%  
Exports to sales %17.234.2 50.2%   
Imports to sales %6.68.3 79.2%   
Exports (fob) Rs m11,36250,050 22.7%   
Imports (cif) Rs m4,36412,203 35.8%   
Fx inflow Rs m14,43551,066 28.3%   
Fx outflow Rs m5,18317,678 29.3%   
Net fx Rs m9,25333,388 27.7%   
CASH FLOW
From Operations Rs m-67,77323,824 -284.5%  
From Investments Rs m-8,768-13,127 66.8%  
From Financial Activity Rs m76,199-13,239 -575.6%  
Net Cashflow Rs m-342-2,478 13.8%  

Share Holding

Indian Promoters % 52.9 16.0 330.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.0 12.2 32.8%  
FIIs % 26.6 23.7 112.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 16.5 26.2 63.0%  
Shareholders   93,274 161,166 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 17, 2017 01:43 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS